Sangeetha Raja

Sangeetha Raja

Auto-generated profile, based on publicly available information

Sangeetha Raja

Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
ASArunkumar Subramanian
Arunkumar Subramanian
RHRajamohamed Haitharali
Rajamohamed Haitharali
NSNirenjen Shanmugasundaram
Nirenjen Shanmugasundaram
TTTamilanban R T
Tamilanban R T
SDSivaraman Dhanasekaran
Sivaraman Dhanasekaran
SRSangeetha Raja
Sangeetha Raja
Background: Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (e.g., Lamotrigine, Carbamazepine, Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides (e.g., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic screening and careful monitoring when prescribing Carbamazepine, especially in populations at higher genetic risk. Case Presentation: A 19-year-old female patient, who had been on Phenytoin and Sodium Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine. Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone, along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops. The patient showed significant improvement and was discharged after fourteen days with followup advice. Conclusion: This case underscores the critical importance of performing genetic testing for the HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy. Such precautionary measures can significantly mitigate the risk of severe adverse reactions like SJS. This report adds to the scientific literature by highlighting the potential dangers associated with anticonvulsant therapies and the necessity for personalized medicine approaches in preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening and vigilant monitoring in the management of patients requiring anticonvulsant medications to prevent serious adverse reactions.

30 September 2024 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SRSangeetha Raja
Sangeetha Raja
ARAkash Rahangan
Akash Rahangan
IPIndumathi Prabath
Indumathi Prabath
JRJamuna Rani
Jamuna Rani

1 July 2026 in Biomedical and Biotechnology Research Journal
Verified
Journal Article
Open access
SRSangeetha Raja
Sangeetha Raja
JRJamuna Rani
Jamuna Rani
Background: Colon adenocarcinoma (COAD) is the most prevalent type of colorectal cancer, originating from glandular cells lining the colon. This study investigated the expression and functional relevance of inflammasome-associated genes (NOD-like receptor family pyrin domain containing 3 [NLRP3], caspase-1 [CASP1], interleukin-1 beta [IL-1 β], and interleukin-18 [IL-18]) in COAD and explored metformin as a repurposed inflammasome modulator. Methods: An integrative in silico approach was employed to analyze the expression, survival significance, and stage specific expression in COAD. Metformin was evaluated through target prediction, absorption, distribution, metabolism, excretion, and toxicity profiling, molecular docking, and 100 ns molecular dynamics (MD) simulations to assess its interaction with inflammasome-associated proteins. Results: Analysis revealed that all four genes are significantly upregulated in COAD. High expression of NLRP3 and IL-1 β strongly predicts poor overall survival and correlates with advanced disease stage, suggesting a pro-tumorigenic role for chronic inflammasome activation in established COAD. While CASP1 was upregulated, its expression level was not prognostic, indicating upstream NLRP3 activation and IL-1 β effector levels are rate-limiting. Metformin was identified as a promising inhibitor with an excellent safety profile. Molecular docking demonstrated strong binding affinities with Pro-caspase, NLRP3, and IL-1 β as key targets. Subsequent 100 ns MD simulations showed that while the IL-1 β-Metformin complex was moderately stable, the IL-18-Metformin complex exhibited greater stability and more persistent key interactions. Conclusions: In conclusion, these computational findings identify the NLRP3 inflammasome as a critical prognostic pathway in COAD and provide a strong mechanistic rationale for validating metformin as a therapeutic modulator of this axis.

20 March 2026 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
SRSangeetha Raja
Sangeetha Raja
SMSatyajit Mohapatra
Satyajit Mohapatra
KAKalaivani Amitkumar
Kalaivani Amitkumar
KNKasthuri Natarajan
Kasthuri Natarajan
JRJamuna Rani
Jamuna Rani
FRFarhana Rahman
Farhana Rahman
Abnormal lipids level leads to hyperlipidemia. Safe and effective therapy is essential for management of hyperlipidemia. Vetiveria zizanioides (VZ), commonly known as vetiver or khus, in traditional medicine shows promising treatment in hyperlipidemia without compromising reproductive health. Aim of this study is to assess antihyperlipidemic effect of aqueous and ethanolic extract from Vetiveria zizanioides in high-fat diet-induced Wistar Albino rats. The aqueous and ethanolic extract of Vetiveria zizanioides was administered orally for 8 weeks at dosage of 300/600mg/kg of wistar albino rats. Body weight, histology and biochemical assessments of the rats were analysed. In-silico evaluation of the Vetiveria zizanioides was done prior to the animal study for the better understanding of the herb. Body weight was decreased 50% in aqueous extract VZ-treated group compared to control group. Biochemical assessments indicate significant decrease in total and LDL cholesterol, triglycerides levels and improvement in HDL levels in high fat diet (HFD) and combination with simvastatin (HFD+SIM) groups (P<0.000). Histology revealed reduction in necrosis and edema while retaining normal spermatogenesis in VZ-treated HFD rats. In in-silico analysis, thirty-six targets were identified between the hypolipidemia and rat testis. Molecular dynamics simulations confirmed the dynamic stability interaction of globulol with highest binding affinity for target proteins 7-dehydrocholesterol reductase (DHCR7) and squalene synthase (FDFT1), with binding energies of -6.8 and -8.6 kcal/mol, respectively and thus ability to modify the protein targets. In conclusion, the in-silico and in-vivo analysis confirmed the antihyperlipidemic activity of Vetiveria zizanioides.